Trial Profile
Oral Immunotherapy Combined With Humanized Monoclonal Anti-IgE Antibody Xolair® (Omalizumab)in the Treatment of Cow's Milk Allergy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Omalizumab (Primary)
- Indications Milk hypersensitivity
- Focus Therapeutic Use
- 13 Apr 2017 Results of a biomarker analysis published in the Journal of Allergy and Clinical Immunology.
- 24 Nov 2015 New trial record
- 30 Oct 2015 Status changed from active, no longer recruiting to completed, as per an article published in the Journal of Allergy and Clinical Immunology